# Aradigm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aradigm

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.aradigm.com
- Total disclosed funding: $20M
- Latest round: Series A (Dec 9, 2025)
- Investors on record: 2

## About

Aradigm is a specialized biotechnology firm focused on developing innovative drug delivery systems that enhance therapeutic efficacy for chronic respiratory diseases. Their unique formulations aim to improve treatment outcomes for patients. Founded in Hayward, US, Aradigm is dedicated to advancing drug delivery technologies. In December 2025, Aradigm raised USD 20 million in series A funding led by new investor Frist Cressey Ventures, with participation from other new investors Andreessen Horowitz and Morgan Health. Aradigm specializes in advanced drug delivery systems designed for chronic respiratory conditions. Their core offerings focus on innovative formulations that improve therapeutic efficacy, catering to the healthcare sector. The products are distributed across North America, Europe, and select Asian markets, serving a diverse clientele ranging from healthcare providers to pharmaceutical companies. Aradigm's revenue model primarily relies on the commercialization of its drug delivery technologies, with clients typically engaging in long-term contracts for product supply. The company plans to utilize the December 2025 funding to speed up the development of its platform and increase collaborations with health systems and insurance providers.

## Funding rounds

- Series A, Dec 9, 2025, $20M — Andreessen Horowitz, Frist Cressey Ventures

## Investors

- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A
- Frist Cressey Ventures (https://capitalatlas.ai/funds/frist-cressey-ventures) — Series A